Breaking News

Sucampo, R-Tech Enter Exclusive Global Mfg. Pact

August 25, 2014

To supply AMITIZA in global markets

Sucampo Pharmaceuticals’ subsidiary, Sucampo AG, has signed an exclusive global manufacturing and supply agreement with its development partner, R-Tech Ueno, Ltd. for clinical and commercial supplies of AMITIZA (lubiprostone) in most global markets.
 
Sucampo will receive a new, lower price for certain components of or finished product of lubiprostone globally, except for the U.S. and Canada until the license agreement with Takeda Pharmaceutical Co., Ltd. expires in December 31, 2020, and except for Japan until the manufacturing and supply agreement expires or certain material circumstances occur.
 
Sucampo has the right to qualify a back-up supplier for lubiprostone in expanded circumstances, such as an authorized generic, additional formulations, and/or inability to supply product in certain circumstances.
 
"Continuing the growth of AMITIZA is the top imperative I outlined earlier this month in my strategic plan for Sucampo. The new agreement will be critical to growing AMITIZA and facilitating our global expansion plans around the world by providing us with greater operational flexibility, lowered overall cost of goods manufactured, and greater margin control," said Peter Greenleaf, chief executive officer of Sucampo. "As we progress our plans to partner AMITIZA globally, including Europe and emerging markets outside of the U.S. and Japan, having greater control over our cost structure will enable us to access markets with tighter reimbursement restrictions. Ultimately, this will make AMITIZA more widely accessible to patients around the world."

blog comments powered by Disqus
  • Elemental Impurity Testing

    Elemental Impurity Testing

    Dr. Andrew Fussell, PANalytical ||January 28, 2016
    Advances in elemental impurity testing aid compliance with new USP requirements

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • Optimizing Collaboration Effectiveness in Alliance Partnerships

    Optimizing Collaboration Effectiveness in Alliance Partnerships

    Mary Jo Lamberti, Phil Birch, Ranjana Chakravarthy, Ken Getz, Tufts CSDD||January 28, 2016